Clinical trial NCT05543746: Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Official title: Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression: a Feasibility Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postpartum Depression
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Baszucki Brain Research Fund
name: Sage Therapeutics
First posted: 2022-09-16
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with moderate to severe PPD, medically eligible to receive FDA-approved BRX infusion, recruited from current inpatient and outpatient population in the Women's Mood Disorders Clinic at UNC and through local advertisements. Subjects recruited from outpatient setting will be individuals for whom BRX is the chosen recommended course of treatment.

Brief summary: This is a feasibility study of performing repeated EEG recordings and assessment of affective states during open-label administration of BRX to women with postpartum depression. Study phases will include screening, enrollment, intervention, and follow-up. Subjects will be screened for study eligibility criteria through clinical assessments and self-report. Enrolled subjects will be admitted to the UNC Women's Hospital, where five serial EEG recordings will be obtained, along with frequent assessments of affective state, before, during, and after a 60-hour IV infusion of BRX. Follow-up procedures will include assessments of PPD and affective symptoms, as well as an exit interview with the study team. If feasibility outcomes are achieved, exploratory EEG analyses will be performed with AMICA (adaptive mixture independent component analysis), community detection, and microstate assessment. Exploratory analyses of data collected by facial expression detection software (iMotions Affectiva) are also planned.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent.
* Documented proof of full COVID-19 vaccination
* Ambulatory, female, aged 18-45
* ≤ 8 months postpartum
* Agrees to adhere to the study requirements.
* Onset of depression in 3rd trimester or within 4 weeks of delivery
* Meets DSM-V criteria for major depressive disorder with peripartum onset.
* 17-item HAM-D total score ≥20 at screening
* Stopped breastfeeding or agrees to temporarily stop for 7 days including 4 days of hospitalization and 3 days after
* No new psychotropic drugs during screening and active treatment of study
* Stable use of any current psychotropic drugs for at least 28 days prior to enrollment, with stable dosage for at least 14 days prior to enrollment
* Must be on documented contraceptive.
* Must have a caregiver or family member with them to help care for the subject's child(ren) during the infusion and to be in the room with the subject if the child(ren) are present during the infusion

Exclusion Criteria:

* Positive pregnancy test at screening or day 1
* Pregnancy that resulted in a stillbirth, termination, or child that was placed for adoption.
* Renal impairment or failure, hepatic impairment or failure, or anemia
* Untreated or inadequately treated hypothyroidism or hyperthyroidism
* Known allergy to progesterone or allopregnanolone.
* Suicide attempt at this episode
* Medical history of schizophrenia, and/or schizoaffective disorder
* Current psychotic symptoms including delusions, hallucinations, or formal thought disorder.
* Concurrent substance abuse
* Exposure to another investigational medication or device within 30 days
* Has previously participated in any study employing brexanolone or SAGE-217.
* Subject is investigative site personnel, sponsor personnel, or an immediate member of their family.
* Has received electroconvulsive therapy during current episode.
* History of seizure disorder
* On anticonvulsant agents
* On benzodiazepines

Primary outcomes:
measure: Number of Successfully Analyzed EEG Recordings
timeFrame: 4 days
measure: Number of Subjects Completing the Entire Study Protocol Through the Follow-up Phase
timeFrame: 30 days
measure: Number of Subjects Withdrawn From Protocol Due to Adverse Events or Participation Burden
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: University of North Carolina
state: North Carolina
Study officials:
affiliation: UNC Chapel Hill
name: Susan Girdler, PhD
role: PRINCIPAL_INVESTIGATOR
References: